Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer

被引:0
作者
Dalia Ahmad Khalil
Danny Jazmati
Dirk Geismar
Jörg Wulff
Christian Bäumer
Paul Heinz Kramer
Theresa Steinmeier
Stefanie Schulze Schleitthoff
Sandija Plaude
Martin Bischoff
Stephan Tschirdewahn
Boris Hadaschik
Beate Timmermann
机构
[1] University Hospital Essen,Department of Particle Therapy
[2] West German Proton Therapy Centre Essen (WPE),Department of Urology
[3] West German Cancer Center (WTZ),undefined
[4] German Cancer Consortium (DKTK),undefined
[5] University Hospital Essen,undefined
[6] University of Duisburg-Essen,undefined
[7] German Cancer Consortium (DKTK),undefined
来源
Radiation Oncology | / 17卷
关键词
Proton therapy; Intensity-modulated therapy; Simultaneous integrated boost; Prostate cancer; Hydrogel prostate-rectum spacers;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 232 条
[1]  
Kuban DA(2008)Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 67-74
[2]  
Tucker SL(2006)Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 1990-1996
[3]  
Dong L(2011)Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes Eur Urol 60 1133-1139
[4]  
Starkschall G(2016)Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Lancet Oncol 17 1047-1060
[5]  
Huang EH(2016)Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial Lancet Oncol 17 464-474
[6]  
Cheung MR(2018)Moderate hypofractionation in intermediate and high risk, localized prostate cancer: Health-related quality of life from the randomized, phase 3 HYPRO trial Int J Radiat Oncol Biol Phys 103 823-833
[7]  
Peeters ST(2018)Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer Adv Radiat Oncol 3 322-330
[8]  
Heemsbergen WD(2018)Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer J Clin Oncol 36 2943-2949
[9]  
Koper PC(2018)Acute toxicity and quality of life in high risk prostate cancer patients: updated results of randomized hypofractionation trial Rep Pract Oncol Radiother 23 284-289
[10]  
van Putten WL(2017)Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer J Clin Oncol 35 1884-1890